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FMS-like tyrosine kinase 3 (FLT3) is the most commonly
mutated gene found in acute myeloid leukemia (AML) patients
and its activating mutations have been proven to be a negative
prognostic marker for clinical outcome. Pacritinib (SB1518) is a
tyrosine kinase inhibitor (TKI) with equipotent activity against
FLT3 (IC50¼22nM) and Janus kinase 2 (JAK2, IC50¼23nM).
Pacritinib inhibits FLT3 phosphorylation and downstream
STAT, MAPK and PI3K signaling in FLT3-internal-tandem
duplication (ITD), FLT3-wt cells and primary AML blast cells.
Oral administration of pacritinib in murine models of FLT3-ITD-
driven AML led to signiﬁcant inhibition of primary tumor growth
and lung metastasis. Upregulation of JAK2 in FLT3-TKI-
resistant AML cells was identiﬁed as a potential mechanism
of resistance to selective FLT3 inhibition. This resistance could
be overcome by the combined FLT3 and JAK2 activities of
pacritinib in this cellular model. Our ﬁndings provide a rationale
for the clinical evaluation of pacritinib in AML including
patients resistant to FLT3-TKI therapy.
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Introduction
Acute myeloid leukemia (AML) is characterized by aberrant
proliferation of myeloid progenitor cells that have lost the ability
to differentiate into mature cells. There are more than 12000
new cases in the United States every year.
1 Up to 35% of AML
patients harbor a mutation in the FMS-like tyrosine kinase 3
(FLT3) gene, a member of the class III receptor tyrosine kinase
family.
2 Constitutively activated mutants of FLT3 have been
shown to be transforming in cultured cell lines and leukemo-
genic in mice.
3 Two major classes of activating mutations have
been identiﬁed: internal-tandem duplications (ITDs) of 3 to
400bp within the juxta-membrane domain or point mutations in
the tyrosine kinase domain.
2 These genetic alterations give rise
to constitutive signaling of FLT3 and activation of downstream
oncogenic pathways, leading to dysregulated cell cycle control
and apoptosis.
4,5 Clinically, FLT3-ITD is a negative prognostic
marker that is associated with increased relapse rate, increased
blast count and poor overall survival.
3,6,7 Overexpression of
wild-type FLT3 in AML patients has been also shown to
increase FLT3 auto-phosphorylation and was an unfavorable
prognostic factor for overall survival.
8 Therefore, aberrantly
activated FLT3 kinase is a validated molecular target for the
treatment of AML.
Several small-molecule FLT3 inhibitors have been evaluated
in clinical trials, either as single agents or in combination with
chemotherapy.
2,9 To date, these candidates either did not
generate sufﬁcient initial response or failed to sustain therapeu-
tic beneﬁt, primarily due to development of secondary
resistance.
10 Clinical data demonstrates that peripheral blood
blasts decline, but bone marrow responses are very rare.
11,12
Among the possible mechanisms for these failures is the
existence of independent alternative survival pathways that
leukemic cells can tap into, either through further genetic
lesions or metabolic adaptation.
2 These pathways may include
components of the mTOR-PI3K-Akt, JAK-STAT or Ras-MAPK
axes.
2 We envisaged that simultaneous targeting of additional
independent pathways will render leukemic cells less likely to
escape FLT3 mono-inhibition. In this respect, targeting JAK2
provides an interesting opportunity due to several pertinent
observations: (a) JAK2 mutations have been reported in rare
cases of AML, (b) phospho-JAK2 has been found to be elevated
in AML primary samples and (c) the suppressor of cytokine
signaling 1/2/3, negative regulators of JAK signaling, have been
found to be downregulated in FLT3-TKI-resistant FLT3-ITD
harboring AML cells.
13,14
Pacritinib is a novel low molecular-weight compound with
potent inhibitory activities against FLT3 and JAK2.
15 We have
previously shown that pacritinib inhibits JAK2-mediated
effects on cellular signaling, functional responses and disease
symptoms in models of myeloid disease generated by activation
of JAK2 signaling.
16 Pacritinib has also shown promising clinical
activity in phase 1/2 trials in advanced myeloid and lymphoid
malignancies.
17,18 Herein, we present new data indicating that
blockade of FLT3 in conjunction with JAK2 signaling could
enhance clinical beneﬁt for AML patients harboring a FLT3-ITD
mutation. This preclinical data provides a rationale for a clinical
evaluation of pacritinib in AML including patients resistant to
FLT3-TKI therapy.
Materials and methods
Compounds and reagents
Pacritinib (SB1518) was discovered and synthesized by S*BIO
Pte Ltd. (Singapore, Singapore).
15,16 Sunitinib was obtained from
Sequoia Research Products Ltd. (Pangbourne, UK). JAK inhi-
bitor 1 (abbreviated as JAKi-1), a pan-JAKi (cat#420099) was
purchased from Calbiochem (Gibbstown, NJ, USA). ABT-869
(linifanib, cat#1638) and VX-680 (cat#1540) were pur-
chased from Axon Medchem BV (Groningen, Netherlands).
INCB018424 (ruxolitinib) was purchased from Active Biochem
(Maplewood, NJ, USA, cat#: A-1134). Stock solutions were Received 1 September 2011; accepted 15 September 2011
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concentration of 0.1% in cell-based assays. For in vivo studies,
dosing solutions were prepared in 0.5% methylcellulose (w/v)
and 0.1% Tween-80 in H2O (MC/Tween). Doses shown are
free-base equivalents of pacritinib.
Cell culture and proliferation assay
SET-2, KG-1, ME-1, SH-2, F36-P, HEL92.7.1, MOLM-13 and
MOLM-16 cells were obtained from DSMZ (Braunschweig,
Germany). MV4-11, THP-1 and HL-60 cells were purchased
from the American Type Culture Collection (ATCC, Manassas,
VA, USA). MV4-11-P and MV4-11-R have been described
previously.
13 All cell lines were cultivated according to the
vendor’s instructions using fetal bovine serum from PAA
Laboratories (Pasching, Austria).
For proliferation assays in 96-well plates, 2000–6000
cells/well were seeded and treated the same day with com-
pounds (in triplicates) at concentrations up to 10mM for 48h.
Cell viability was monitored using the CellTiter-Glo assay
(Promega, Madison, WI, USA). Dose response curves were
plotted to determine IC50 values for the compounds using the
XL-ﬁt software (IDBS Ltd., Alameda, CA, USA).
To determine the in vitro synergy of two drugs they were
combined at a constant ratio (based on the individual drug’s
IC50), with nine concentration steps, threefold dilutions and
the highest dose used being 8  IC50 concentrations.
19 Synergy
was determined using the CompuSyn software (v2007;
ComboSyn Inc., Paramus, NJ, USA).
Primary cells, either peripheral blood mononuclear cells or
bone marrow mononuclear cells from AML patients were
obtained from AllCells (Emeryville, CA, USA) and ProteoGenex
(Culver City, CA, USA). Cells were thawed and expanded as
described earlier.
20 Between day 10 and 13, the expanded
blasts were counted on a Z1 Coulter Particle Counter (Beckman
Coulter Inc., Brea, CA, USA) and aliquoted as follows: B1 10
5
cells for FLT3 genotyping (as described earlier),
20 B5 10
5 cells
for FACS analysis and B3 10
6 cells for a proliferation assay.
Caspase-3/7 assay
MV4-11 cells (100ml) or AML blast cells (300000cells/ml) were
treated with pacritinib in a concentration range between 10mM
and 0.5nM for 16h. Caspase-3/7 activity was measured using
the Promega Caspase-Glo 3/7 assay (#TB323, Promega).
Flow cytometry
For cell cycle analysis, 5 10
5cells/ml MV4-11, MOLM-13 and
RS4;11 cells were treated for 24h at the IC50 for viability of
pacritinib. After treatment, cells were ﬁxed using 70% ice-cold
ethanol and stained with 20ng/ml propidium iodide (BD
Biosciences, Franklin Lakes, NJ, USA). For apoptosis analysis,
MV4-11 cells were treated with 0.03 and 0.15mM pacritinib for
48 and 72h and stained using the AnnexinV-FITC apoptosis
detection kit from BD Biosciences, according to the manufac-
turer’s instructions. To characterize expanded AML blasts, cells
were labeled with monoclonal antibodies against CD123
(#558663, BD Biosciences) and analyzed on a FACSCalibur
equipped with the CellQuest Pro software (BD Systems,
San Jose, CA, USA).
Western blot analyses
Cell lysis, protein quantiﬁcation and western blots were
performed as described previously.
21 Following SDS-polyacry-
lamide gel electrophoresis, proteins were transferred to
polyvinylidene diﬂuoride membranes. Western blots were per-
formed according to standard methods. pFLT3 (Y591)
(cat#3461), pSTAT3 (Y705) (cat#9135), pAkt (T308)
(cat#4056), pAKT(T473) (cat# 9271), pp44/42 (T202/Y204)
(cat#9101), anti-mouse IgG (cat#7074), and anti-rabbit IgG,
HRP-linked (cat#7076) antibodies were purchased from Cell
Signaling Technology (Beverly, MA, USA). pSTAT5 (Y694,
cat#611965) was obtained from BD Biosciences (San Jose, CA,
USA) and a ˆ-actin (cat#2066) from Sigma (St Louis, MO, USA).
Animal models
Female athymic BALB/c nude mice (BALB/cOlaHsd-Foxn1
nu)
were obtained from the Biological Resource Centre (Biopolis,
Singapore) and were 9-16 weeks of age at the time of tumor
implantation. Standard protocols were followed, in compliance
with the National Institutes of Health and National Advisory
Committee for Laboratory Animal Research guidelines (IACUC
approval 0800371). Female BALB/c nude mice were implanted
subcutaneously in the right ﬂank with 1 10
7 MV4-11 human
AML cells. Cells were re-suspended in 50ı `l serum-free growth
medium, mixed 1:1 with Matrigel (cat. No: 354248; BD
Bioscience) and injected in a total volume of 100ml, using a
27-gauge needle. Tumor growth was measured twice per week
using a caliper. For the efﬁcacy study animals were randomized
on day 11 after inoculation (study day 0) into 4 treatment
groups, with a mean tumor volume of 146–150mm
3. Statistical
analyses on tumor growth inhibition or tumor weight (one-way
analysis of variance, followed by Dunnett’s post-test) were
performed using Prism 5 (GraphPad Software, La Jolla, CA,
USA). For the PK-PD study the average starting tumor volume
was 328mm
3 (range 144–550mm
3). For the MOLM-13s.c.
model, 5 10
6 MOLM-13 cells were injected in 0.2ml serum-
free medium into the right ﬂank of female mice severe
combined immunodeﬁciency (C.B-17/IcrHan, Hsd-Prkdcscid)
(Biolasco, Taipeh, Taiwan). Tumor volumes were determined by
caliper measurements. After 15 days when tumors had reached
a mean volume between 536 and 596mm
3, mice were
randomized into three groups of 12 animals each and drug
treatment was initiated. Treatment was orally administered b.i.d.
for 8 consecutive days. All animals were killed 3h post-dose on
day 7 and the tumors harvested. Tumor growth inhibition was
calculated as described previously.
21 All statistical analyses
were performed with GraphPadPrism 5.
Results
Pacritinib modulates FLT3 signaling pathways
Pacritinib is a small-molecule inhibitor of JAK2 (IC50¼23nM)
with selectivity for JAK2 within the JAK family (JAK1
IC50¼1280nM, JAK3 IC50¼520nM, TYK2 IC50¼50nM) and
targets FLT3 (FLT3-wt IC50¼22nM, FLT3-D835Y IC50¼6n M)a t
the same concentration range as JAK2.
16
To investigate whether its enzyme inhibitory properties
translate into modulation of FLT3 signaling pathways in the
cellular context, the effects of pacritinib on FLT3 auto-
phosphorylation (pFLT3 Y591) and downstream STAT5 phos-
phorylation (pSTAT5 Y694), pERK1/2 (T202,Y204) and pAkt
(T308) were investigated in two FLT3-ITD-harboring cell lines
(MV4-11 and MOLM-13) and one FLT3-wt-bearing cell line
(RS4;11).
FLT3-ITD harboring MV4-11 cells were treated for 3h with
different concentrations of pacritinib and pFLT3, pSTAT5 and
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dependent decrease of pFLT3, pSTAT5, pERK1/2 and pAkt with
IC50 of 80, 40, 33 and 29nM, respectively (Figure 1a). Similar
potencies in inhibition of FLT3 signaling were achieved in
the second FLT3-ITD cell line, MOLM-13, with IC50 of 180
and 20nM on pFLT3 and pSTAT5, respectively (Figure 1b). To
ascertain that the inhibition of FLT3 signaling is independent
of the JAK2 activity of pacritinib, we treated the cells with the
JAKi-1 (a selective pan JAKi) and analyzed the cells for pFLT3.
Concentrations up to 1000nM of this potent pan-JAKi did not
reduce FLT3 phosphorylation (Figure 1a). Treatment of the cells
with sunitinib, a multi-kinase inhibitor with FLT3 (IC50¼3n M)
but no JAK2 activity, resulted in a potent inhibition of FLT3
signaling. To extend the evaluation of the effects of pacritinib to
FLT3-wt signaling, RS4;11 cells were treated with various
concentrations of pacritinib. The IC50 on auto-phosphorylation
of FLT3-wt in RS4;11 was fourfold higher (IC50¼600nM)
compared with FLT3-ITD in MV4-11 and MOLM-13 cells.
However, STAT5 inhibition was detected at much lower
concentrations of pacritinib (IC50¼8n M) (Figure 1c).
Overall, these data demonstrate that pacritinib effectively
permeates leukemia cells to modulate FLT3 signaling pathways
in cell lines driven by constitutively activated or ligand-
activated FLT3.
Pacritinib induced apoptosis, cell cycle arrest and anti-
proliferative effects in FLT3-mutant and FLT3-wt cells
As FLT3 signaling has a key role in important functional
responses such as cell proliferation and survival, the effects
of pacritinib on cell cycle and apoptosis were investigated.
MV4-11 cells were treated with pacritinib (0.03 and 0.15mM) for
48 or 72h and analyzed for induction of apoptosis using
Annexin V staining.
Pacritinib dose dependently increased cell populations in
early and late stage apoptosis, without inducing necrosis
(Figure 2a). The ability of pacritinib to induce apoptosis is also
evident in Figure 2b where caspase-3/7 was dose dependently
activated. To determine whether pacritinib treatment leads to a
cell cycle arrest, FLT3-ITD and FLT3-wt cell lines were treated
with pacritinib for 24h. Figure 2c showed that 24h of exposure
to pacritinib arrested both FLT3-ITD- and FLT3-wt-expressing
cells at G1 phase and decreased the S-phase population
in a dose-dependent manner. The IC50 of pacritinib on cell
proliferation in RS4;11 (FLT3-wt) cells was 15-20-fold higher
(IC50¼930nM) compared with FLT3-ITD-harboring cells MV4-11
(IC50¼47nM) and MOLM13 (IC50¼67nM) (Figure 3).
16
These results indicate that inhibition of FLT3 signaling by
pacritinib in cancer cells can lead to G1 arrest and caspase-
dependent apoptotsis, with FLT3-ITD harboring cells being the
most sensitive.
Pacritinib blocks proliferation in FLT3-ITD- or
JAK2V617F-driven AML cell lines
The anti-proliferative effect of pacritinib was tested on 11 AML-
derived cell lines with different French-American-British classi-
ﬁcation. Interestingly, pacritinib showed the highest potency in
French-American-British classiﬁcation M5 subtypes (THP-1,
MV4-11 and MOLM-13), with the FLT3-ITD status further
differentiating the last two cell lines from THP-1. Furthermore,
the JAK2
V617F-harboring cell line, SET-2, was also very sensitive
to pacritinib (IC50¼0.22mM, Figure 3). The data reﬂects the
on-target speciﬁcity of pacritinib across diverse AML cell lines.
Figure 1 Pacritinib effectively blocks FLT3 signaling in FLT3-ITD (MV4-11, MOLM-13) or FLT3-wt (RS;4-11) cells. (a) MV4-11 cells were treated
with pacritinib, JAKi-1 and sunitinib for 3h as indicated. After lysis, phosphorylation status of FLT3, STAT5, ERK1/2 and Akt were detected by
immunoblotting (IB). As a loading control, the same membranes were re-probed with anti-actin antibody. (b) MOLM-13 and (c) RS4;11 cells were
pre-treated with pacritinib for 3h and stimulated for 3min with 10ng/ml FLT3 ligand as indicated. After lysis, the phosphorylation status of FLT3
and total actin were detected by IB.
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and apoptosis in ex-vivo expanded primary AML blast cells
Having demonstrated that FLT3 inhibition leads to cell cycle
arrest and apoptosis in established AML cell lines, it was
pertinent to investigate whether pacritinib treatment could
also compromise the viability of primary AML blast cells.
The expanded AML blasts were analyzed using FACS and more
than 90% of cell population from each sample were found to
express the IL-3 receptor-a chain (CD123), a distinctive marker
for human AML stem cells (Supplementary Figure 1).
22 This
conﬁrmed that the expanded cells were the intended popula-
tion. Patient characteristics for the 14 AML samples are shown in
Supplementary Table 1. Treatment of the AML blast cells with
pacritinib for 3h led to a dose-dependent decrease of pFLT3,
pSTAT3 and pSTAT5 with an IC50 below 0.5mM (Figure 4a).
The most sensitive sample to the anti-proliferative effect of
pacritinib had an IC50 of 190nM and the most resistant sample
had an IC50 of 1300nM (Figure 4b). The two samples harboring
the FLT3-ITD mutation were among the most sensitive
to pacritinib treatment. The relatively high sensitivity of the
FLT3-wt blasts may be because the expansion medium
contained FLT3-L, which would have activated FLT3 signaling
in these cells. The inhibition of FLT3 signaling in the AML blast
cells resulted in G1 cell cycle arrest and induction of caspase-
dependent apoptosis (Figures 4c and d).
These data demonstrate that pacritinib induces FLT3 pathway
inhibition and concomitant G1 cell cycle arrest and apoptosis in
primary AML primary blasts as well as cell lines.
Pacritinib is efﬁcacious in FLT3-ITD-bearing MV4-11
and MOLM-13 xenograft models
For evaluation of the in vivo efﬁcacy of pacritinib on FLT3-ITD
driven tumors, MV4-11 and MOLM-13 xenografts were
Figure 2 Pacritinib induces cell cycle arrest and apoptosis in FLT3-ITD- (MV4-11, MOLM-13) and FLT3-wt- (RS;4-11) harboring cancer cells.
(a) MV4-11 cells were treated for 48 or 72h with pacritinib followed by AnnexinV and propidium iodide co-staining. The left lower quadrant
shows live cells, the left upper quadrant necrotic cells, the right lower and the right upper quadrant early and late apoptotic cells, respectively. The
percentage of cells in each quadrant are indicated. (b) MV4-11 cells were treated with pacritinib for 16h and caspase-3/7 activity was determined.
An EC50 of 0.96mM was calculated using the XL-ﬁt software. (c) MV4-11, MOLM-13 and RS4;11 cells were treated for 24h with pacritinib as
indicated and cell cycle analysis was performed using propidium-iodide staining followed by ﬂow cytometric measurement.
Figure 3 Pacritinib inhibits proliferation of AML cells with highest
potency in FLT3-ITD harboring cells. Cells were treated for 48h with
pacritinib followed by the CellTiterGlo assay.
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mice. To demonstrate target engagement by pacritinib in the
tumor tissues, tumor-bearing mice were ﬁrst given a single dose
of 150mg/kg pacritinib and tumor samples taken at 2 and 4h
(MV4-11) or 3h (MOLM-13) and the tumor lysates were
analyzed for FLT3 signaling. In both xenograft models, acute
pacritinib treatment was able to block FLT3 and downstream
signaling (Figures 5a and b) in the tumors. To identify a
possible effect on tumor growth, MV4-11 tumor-bearing mice
(average starting tumor size of 130mm
3) were treated once daily
for 21 consecutive days. Pacritinib treatment induced dose-
dependent inhibition of tumor growth (38% for 25mg/kg,
92% for 50mg/kg and 121% for 100mg/kg, Figure 5c). Complete
regression was observed in 3/10 and 8/8 mice for the 50 and
100mg/kg/day groups, respectively. All doses were well tolerated
with no signiﬁcant body weight loss (data not shown).
In contrast to the MV4-11 efﬁcacy study, the average
tumor volume was much higher (543mm
3) when treatment
commenced in the MOLM-13 model. Treatment with 150mg/kg
b.i.d. for 7 consecutive days resulted in a tumor growth
inhibition of 83% (Figure 5d). Analysis of the FLT3 signaling
pathway in the tumor lysates 3h after the last dose on day 7
showed a full inhibition of STAT5 phosphorylation (Figure 5e).
In addition, post-mortem analysis showed that metastatic
incidence (mostly in the lungs) was signiﬁcantly reduced from
0.83 to 0.33 in the high-dose pacritinib group (Figure 5f).
These results demonstrate that treatment of FLT3-dependent
tumors by pacritinib not only reduces the growth of the primary
tumor, but also the formation of metastasis.
Selective FLT3-TKI up-regulates JAK2 signaling in
FLT3-ITD-harboring AML cells
It has been proposed that one of the mechanisms of secondary
resistance to FLT3-TKI in AML patients arises from enhanced
STAT signaling.
13 Therefore we investigated, whether MV4-11
cells resistant to the FLT3-TKI linifanib/ABT-869 (MV4-11-R)
shows higher JAK/STAT signaling compared with the parental
MV4-11 (MV4-11-P) cells. Western blot analysis clearly shows,
that both pJAK2(Y1007/8) and total JAK2 are signiﬁcantly
increased in MV4-11-R compared with MV4-11-P (Figure 6a).
This result prompted us to explore whether acute treatment of
MV4-11 cells with FLT3-TKI enhances JAK2 signaling in any
way. Linifanib, sunitinib and VX-680 are FLT3-TKI without any
signiﬁcant activity against JAK2. MV4-11 cells were treated
with linifanib, sunitinib and VX-680 for 24h at the IC50 of cell
proliferation and JAK2 signaling determined by western blot
analysis. All three compounds increased pJAK2 signaling in
the MV4-11 cells without changing total JAK2 protein levels
(Figure 6b).
Having shown that JAK2 signaling is upregulated in MV4-11-R
cells, we wondered if combined inhibition of JAK2 and FLT3
can nullify the resistance to FLT3i in MV4-11-R cells. Linifanib,
a FLT3-TKI, is 127 times more potent against MV4-11-P
compared with MV4-11-R (Figure 6c). Sunitinib, a multi-kinase
inhibitor with FLT3 but not JAK2 activity, showed a 14-fold
difference in potency of MV4-11-P compared with MV4-11-R.
Pacritinib, a dual inhibitor of FLT3 and JAK2, showed only a
2.9-fold difference, with a high sensitivity of both cell lines
(IC50¼153 and 434nM for MV4-11-P and MV4-11-R, respec-
tively) indicating that JAK2 inhibition may overcome the
resistance to FLT3 inhibition. Consistent with this, the JAK
family inhibitor ruxolitinib, which has no FLT3 activity
and is only active on the MV4-11-P at extremely high
concentrations (IC50¼19.5mM), showed an opposite trend,
being sevenfold more potent against MV4-11-R cells
(IC50¼2.7mM). Taken together these data demonstrate
the enhanced JAK2 dependency in MV4-11-R compared with
MV4-11-P cells.
Figure 4 Pacritinib blocks proliferation and induces apoptosis in ex vivo expanded primary AML blast cells. (a) On day 12 of the ex vivo
expansion protocol of AML blast cells, cells were treated with pacritinib 0.5 and 2mM for 3h. After lysis, the phosphorylation status of FLT3, STAT3
and STAT5 were detected by immunoblotting. (b) AML blasts were treated with pacritinib for 48h and the IC50 for proliferation was evaluated
using the CellTiter-Glo assay. (c) AML blasts were treated with 0.47mM pacritinib for 48h and cell cycle analysis was performed using propidium-
iodide staining followed by ﬂow cytometric measurement. (d) AML blasts were treated with pacritinib for 16h and the EC50 on induction of
apoptosis was determined by measuring caspase-3/7 activity.
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MV4-11 cells within 24h following acute treatment with FLT3
inhibitors and to further demonstrate that this is a resistance
mechanism, we investigated whether combining a JAK2
inhibitor without signiﬁcant FLT3 activity with a FLT3 inhibitor
without signiﬁcant JAK2 activity, might be synergistic. Indeed,
Figure 5 Pacritinib is efﬁcacious in xenografts derived from cell lines harboring FLT3-ITD. (a) MV4-11 tumor-bearing mice received an acute
dose of 150mg pacritinib. At 2 and 4h after dosing, mice were killed and tumors harvested. Phosphorylation status of STAT5 and total actin was
determined by immunoblotting. (b) MOLM-13 tumor-bearing mice received an acute dose of 150mg pacritinib. At 3h after dosing, mice were
killed and tumors harvested. Phosphorylation status of FLT3, STAT3, STAT5, Akt and total actin were determined by immunoblotting. (c) MV4-11
tumor-bearing nude mice (n¼10/group) were treated daily for 21 days with the indicated doses of pacritinib hydrochloride salt or vehicle
(MC/Tween). Doses shown are free base equivalents of pacritinib. The tumor growth inhibition (TGI) is indicated. Analysis of variance (ANOVA)
with Dunnett’s post-test was performed, ***Po0.001. (d) MOLM-13 tumor-bearing nude mice (n¼12/group) with an average tumor volume
between 548 and 596mm
3 were treated daily for 8 days with the 150mg/kg b.i.d. pacritinib citrate salt or vehicle (MC/Tween). Doses shown are
free base equivalents of pacritinib. The TGI is indicated. ANOVA with Dunnett’s post-test was performed, ***Po0.001. (e) At 3h after the last
treatment on day 7, MOLM-13 tumor bearing-mice were killed and tumors harvested. Phosphorylation status of STAT5 and total actin were
determined by immunoblotting. (f) On day 7, MOLM-13 tumor-bearing mice were killed and analyzed for tumor metastasis (n¼12/group).
Unpaired t-test was performed, *Po0.05.
Figure 6 Activated JAK2 signaling in MV4-11 cells after selective inhibition of FLT3 induces FLT3-TKI resistance. (a) Parental MV4-11 cells (MV4-
11-P) and linifanib-resistant MV4-11 cells (MV4-11-R) were lysed and pJAK2 and total JAK2 were detected by immunoblotting. (b) MV4-11 cells
were treated with linifanib, sunitinib and VX-680 for 24h. After lysis, pJAK and pFLT3 were detected by immunoblotting (IB). (c) Cells were treated
for 48h with various concentrations of pacritinib, ruxolitinib, sunitinib and linifanib followed by the CellTiterGlo assay.
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JAKi-1 resulted in a conﬁdence interval value of 0.73 and 0.8 for
ED50 and ED90 respectively, reﬂecting the synergy of the
two compounds (Supplementary Table 2). Similar data were
obtained with the combination of linifanib and ruxolitinib
(data not shown).
In summary, acute and chronic treatment of MV4-11 cells
with FLT3-TKI leads to increased JAK2 signaling as a resistance
mechanism. FLT3-TKI resistance can be reduced by additional
JAK2 inhibition. Pacratinib provides these properties as a
monotherapy and is highly effective in the parental and
FLT3-TKI-resistant MV4-11 lines.
Discussion
FLT3 kinase, which is genetically altered in up to 35% of AML
patients, is considered an attractive therapeutic target for this
indication.
7,23 Various FLT3-TKIs, like linifanib, sunitinib,
CEP-701, PKC412, AC-220 and MLN518 have been studied in
clinical trials in AML patients, either as a single agent or
in combination with standard chemotherapy.
24–27 These studies
have shown initial clinical responses, which were not sustained
over the long term as patients developed resistance to the
drug.
28,29
Pacritinib is a novel JAK2 inhibitor selective for JAK2 within
the JAK family and equipotent against FLT3.
15,16 It is currently in
phase II clinical trials for myeloﬁbrosis and lymphoma where it
is showing promising clinical activity and a favorable safety
proﬁle. We have previously reported its pharmacological proﬁle
and efﬁcacy in preclinical models of JAK2-driven myeloid and
lymphoid malignancies.
16 Herein we describe its efﬁcacy in
preclinical models of AML and provide a rationale for clinical
trials in this indication.
Our present data demonstrate that pacritinib potently inhibits
FLT3 auto-phosphorylation and downstream STAT5, MAPK and
PI3K signaling pathways in AML cell lines with highest potency
against cells harboring FLT3-ITD mutations. Blockade of FLT3
signaling was also demonstrated in primary AML blasts treated
ex-vivo with pacritinib. In both cell lines and primary blasts,
pacritinib treatment led to the induction of G1 arrest, inhibition
of cell proliferation, as well as caspase-dependent apoptosis.
The anti-proliferative effects of pacritinib on the FLT3-ITD
harboring cell lines MV4-11 (IC50¼47nM) and MOLM-13
(IC50¼67nM), which have been reported previously,
16 are in
the same range as the inhibition of intracellular FLT3 signaling.
Pacritinib was highly efﬁcacious in blocking tumor growth in
mouse subcutaneous xenograft models generated with the
FLT3-ITD-harboring cell lines, MV4-11 and MOLM-13. In the
MV4-11 model, pacritinib dose-dependently blocked tumor
growth and the highest dose led to complete tumor regression in
all mice. Similarly, in mice with well established and aggressive
MOLM-13 tumors, (average tumor size of 536–596mm
3),
pacritinib decreased FLT3 phosphorylation and downstream
STAT5 signaling in tumor tissue and led to 83% tumor growth
inhibition after 7 days of dosing. In contrast, linifanib, a multi-
targeted receptor tyrosine kinase inhibitor with 4nM FLT3
activity but no activity on JAK2, is reported to show only a
modest effect on the inhibition of growth of large MOLM-13
tumors.
30 Interestingly, intra-pulmonary leukemic deposits were
observed in the vehicle group of the MOLM-13 xenograft model
and pacritinib treatment signiﬁcantly reduced these deposits
(Figure 5f). AML patients have been reported to develop
extramedullary granulomas in the lung or liver.
31 Our ﬁndings
suggest that besides limiting the growth of the primary tumor,
pacritinib may also have the potential to reduce extramedullary
leukemic growth in patients with AML.
Increasingly, other targets besides FLT3 have been suggested
as potential therapeutic targets for AML due to the development
of secondary resistance to FLT3-TKI. Examples include casein
kinase 2 alpha (CK2a), CD47, CD123, PIM, mTORC1, PI3K and
JAK2.
32–36 Recent observations indicate that high levels of
phospho-JAK2 are associated with adverse clinical outcomes in
AML.
14 Furthermore, a selective JAK2 inhibitor with no FLT3
activity, namely AZ-960,
37 has been shown to inhibit clono-
genic growth and induce apoptosis in freshly isolated AML
cells.
14 The authors concluded that JAK2 is a bona ﬁde target for
AML therapy. Recent publications suggested that therapeutic
outcomes can be signiﬁcantly improved with co-inhibition of
FLT3 and the JAK/STAT pathway.
13 Inhibition of STAT5
signaling by a small molecule inhibitor of JAK2 is reported to
sensitize leukemia stem cells to FLT3 inhibitors.
38 In addition,
FLT3 inhibitor-resistant MV4-11-R cells have been shown to
arise from hyper-activated STAT pathways due to downregula-
tion of suppressor of cytokine signaling proteins but not
PI3K/AKT or the MAPK pathway.
13
In the present studies, we have shown that JAK2 signaling is
activated in MV4-11 parental cells after acute treatment with
FLT3-TKI as well as in a FLT3-TKI-resistant MV4-11-R cell line.
An acquired JAK dependency in the FLT3-TKI-resistant cells was
demonstrated by a sevenfold increased sensitivity of these cells
to a JAKi devoid of FLT3 activity and the high sensitivity of these
resistant cells to pacritinib. Moreover, co-treatment of MV4-11
cells with a JAK2 inhibitor devoid of signiﬁcant FLT3 activity,
with a FLT3 inhibitor devoid of signiﬁcant JAK2 activity, showed
a synergistic effect in inhibiting cell proliferation. Our data
strongly argues for the combined inhibition of FLT3 and JAK2 in
FLT3-ITD-positive patients in two scenarios: as a ﬁrst-line
therapy to minimize the development of secondary resistance
or as a second-line therapy to re-sensitize resistant cells to FLT3
inhibition. Lestaurtinib (CEP-701), a potent JAK2/FLT-3 inhibitor,
has been recently tested in a phase II trial in AML patients with
mutant FLT3 following chemotherapy. The study showed
that FLT3 inhibition highly correlated with remission rate.
39
However, the drug failed to provide long-term beneﬁts for the
patients. The authors suggested that the pharmacokinetic
properties of lestaurtinib, which include signiﬁcant variations
in steady-state plasma levels and decreasing plasma levels over
the course of treatment, might explain the failure.
39
Pacritinib, with its combined potent JAK2/FLT3 inhibition and
a favorable pharmacokinetic and safety proﬁle that is now
established in patients, may have a better chance of success. The
JAK2 activity of pacritinib provided the rationale for its current
clinical evaluation in patients with myeloﬁbrosis and lympho-
ma. Importantly, these trials have demonstrated not only durable
clinical beneﬁt, but also favorable pharmacokinetics properties
and a safety proﬁle that includes no overt myelosuppres-
sion.
18,40 Interestingly, seven AML patients were included in
one of the phase 1 myeloid malignancy studies and three of these
patients showed clinical beneﬁts (two stable diseases and one
clinical improvement).
41 Taken together, the promising preclinical
proﬁle as well as the emerging clinical data provide a compelling
rationale for a more extensive clinical evaluation of pacritinib in
AML, including patients resistant to FLT3-TKI therapy.
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